A Phase 1a/1b, Multicenter, Open-label, Dose Escalation/Expansion, Multiple-dose Study to Evaluate the Safety and Activity of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas

Inclusion Criteria: * Histologically confirmed epithelial cancer of the following tumor types: breast (TNBC, HR+/HER2-/+BC), NSCLC, cervical, CRPC, PDAC, HNSCC, endometrial, ovarian, gastric/GEJ, or urothelial that is unresectable, locally advanced or metastatic * Relapsed or refractory with at least 2 prior lines of therapy and for which no standard of care treatment options are available * Radiographically measurable disease * Eastern Cooperative Oncology Group (ECOG) performance status 0-1 * Life expectancy, in the opinion of the Investigator, of ≥ 3 months * Adequate marrow reserve, renal…